Key result
The PFA-100/200 is a valuable tool for screening and monitoring primary hemostasis disorders, though its closure time results lack specificity for individual conditions.
Answers are grounded in this paper and cite their sources.
The PFA-100/200 is a useful global screening tool for primary hemostasis disorders and monitoring therapy, though it lacks diagnostic specificity.
The "platelet function analyzer" (PFA)-100 was first introduced to us in 1995. Since then, the instrument has appeared in over 50 reviews and almost 1000 publications. Recently, the PFA-100 has been "upgraded" to the PFA-200, which has transformed the user interface and electronic management, but retained the fundamental mechanics, and essentially provides the same results. The PFA-100/200 has conceivable clinical utility to screen for von Willebrand Disease (VWD) and platelet disorders, and in monitoring desmopressin (DDAVP) therapy in both, and possibly anti-platelet therapy. Its great strengths are its usage simplicity and sensitivity to conditions affecting primary hemostasis. However, as a "global" test, its limitation is that closure time (CT) test results are neither predictive of, nor specific for, any individual disorder. However, utilized properly, the PFA-100/200 reflects a valuable addition to hemostasis laboratories involved in identification or therapeutic-monitoring of disorders of primary hemostasis.
No takes yet. Share an insight, caveat, or question.
Emmanuel J. Favaloro (2016) conducted a review in von Willebrand Disease (VWD) and platelet disorders. Platelet function analyzer (PFA)-100/200 was evaluated. The PFA-100/200 is a valuable tool for screening and monitoring primary hemostasis disorders, though its closure time results lack specificity for individual conditions.
Synapse has enriched 10 related papers. Consider them for comparative context: